Why I opened the Ipamorelin file.
The word medicine makes a promise that an interesting molecule still has to earn.
A tolerated meal is an unusually good question
I expected the Ipamorelin papers to revolve around hormone measurements. The bowel-resection trial brought the subject down to something ordinary: whether a person could tolerate a meal sooner after surgery. That change of scale, from a receptor to a plate of food, is the reason this site exists.
Ipamorelin Meds is one person's account of published research, not medical advice. The distance between a clever pharmacological result and a useful medicine interests me. The early selectivity finding deserves admiration. The failed clinical endpoint deserves at least as much attention. A reputation that leaves room for only the first of those is incomplete.
A folder marked Meds
I'm no doctor. Ipamorelin Meds names this collection of papers and questions; it is not a medical practice or a shop. This site prescribes, sells, ships and books nothing. There is no consultation or treatment here, and none of these pages can assess a person's health.
The medicine-sized name is useful precisely because the development file remains unfinished. I don't regard a research label as a patient-care standard, or a growth-hormone pulse as evidence of every benefit attached to it online. The practical questions are harder than the name makes them sound.
An open file can contain a firm objection
The mouse adiposity finding has eroded my patience with a general body-composition story. The specific results are more interesting anyway: rat bone growth without a matching total IGF-1 change, protection against chemotherapy-associated weight loss in ferrets without preventing vomiting, and hormone synergy measured with other peptides.
I object whenever a conclusion outruns its own experiment. A direct human outcome study of the popular combination, with meaningful follow-up for safety, would add something this file does not presently have. Until then, the selectivity remains interesting, the clinical disappointment remains real, and the combination remains a research extrapolation.